First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study

A.Chan; V.Ganju; D.Becquart; P.F.Conte; L.Petruzelka; L.Goedhals; M.Gil Gil; G.Bernardo; G.Villanova; N.Tubiana-Mathieu

首页> 外文期刊>European Journal of Cancer Supplements >First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study

【24h】

First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study

机译：一线曲妥珠单抗（H），口服长春瑞滨（NVBo）和卡培他滨（X）联合治疗HER2阳性转移性乳腺癌（MBC）：一项跨国II期研究的有效性和安全性

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第7期|共2页
作者
A.Chan; V.Ganju; D.Becquart; P.F.Conte; L.Petruzelka; L.Goedhals; M.Gil Gil; G.Bernardo; G.Villanova; N.Tubiana-Mathieu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2008,第7期

机译：一线曲妥珠单抗（H），口服长春瑞滨（NVBo）和卡培他滨（X）联合治疗HER2阳性转移性乳腺癌（MBC）：一项跨国II期研究的有效性和安全性
2. 5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2009,第2期

机译：5055口服长春瑞滨（NVBo），卡培他滨（X）和曲妥珠单抗（H）联合治疗在HER2阳性转移性乳腺癌（MBC）中的疗效：一项国际II期试验的更新结果，平均随访39个月
3. 5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2009,第2期

机译：5055口服长春瑞滨（NVBo），卡培他滨（X）和曲妥珠单抗（H）联合治疗在HER2阳性转移性乳腺癌（MBC）中的疗效：一项国际II期试验的更新结果，平均随访39个月
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial [O] . Winston W. Tan, Jacob B. Allred, Muhammad Salim, -1

机译：Capecitabine的II期介入研究（N0337）与血列林和曲妥珠单抗组合的HER2阳性转移性乳腺癌的第一或二线治疗：北中央癌症治疗组试验
7. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results [O] . Edith A. Perez, José Manuel López-Vega, Thierry Petit, 2016

机译：长春瑞滨联合培妥珠单抗和曲妥珠单抗联合治疗HER2阳性局部晚期或转移性乳腺癌患者的一线治疗的安全性和有效性：VELVET研究组1的最终结果

First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study

著录项

相似文献

相关主题

期刊订阅